• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Lemborexant and Sleep Architecture in the Elderly

Lemborexant and Sleep Architecture in the Elderly

August 3, 2021
Garrett Rossi, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Garrett Rossi, MD. Dr. Rossi has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

REVIEW OF: Moline M et al, J Clin Sleep Med 2021. Epub ahead of print.

TYPE OF STUDY: Randomized, double-blind, parallel-group study

As we age, sleep architecture worsens in ways that reduce sleep quality, particularly after age 55. Unfortunately, most hypnotics either do not improve sleep quality (eg, the z-hypnotics) or slightly worsen it (eg, the benzodiazepines). Specifically, benzodiazepines in higher doses can reduce stages of sleep that are critical for memory consolidation. Lemborexant (Dayvigo) was approved in 2019 for the treatment of insomnia in adults. Its effects are mediated by dual orexin receptor antagonism. Recently, researchers looked at how sleep architecture changed when older adults took this orexin antagonist.

The study was a secondary analysis of an industry-sponsored, randomized, double-blind trial of 1006 subjects known as SUNRISE 1. All subjects were over age 55 (average 63) and had primary insomnia; the majority were female (86%) and white (72%). The presence of sleep-maintenance insomnia was required; some subjects had sleep-onset insomnia as well. Patients with significant depression, anxiety, or substance use (including caffeine use after 6 pm) were excluded. Also excluded were patients with medical problems that could make hypnotic use unsafe, and those with comorbid sleep disorders (eg, sleep apnea, periodic limb movement disorder, restless legs syndrome, circadian rhythm sleep disorder, and narcolepsy).

Patients were randomly assigned to one of four conditions: lemborexant 5 mg, lemborexant 10 mg, zolpidem ER 6.25 mg, or placebo. Participants were treated for 30 nights followed by a follow-up period of 14 days before the end-of-study visit. The goal of this secondary analysis was to compare changes in sleep architecture (eg, total sleep time, non-REM sleep, and REM sleep) in older adults with insomnia disorder receiving lemborexant (5 or 10 mg), zolpidem, or placebo.

After a month of treatment, both doses of lemborexant outperformed placebo and zolpidem on measures of sleep architecture. Specific sleep architecture changes included increased total sleep time, non-REM sleep, and REM sleep, as well as reduced REM latency after the first 2 nights of treatment and again after a month of treatment. After 30 days, both doses of lemborexant increased total sleep time by about twice as much as placebo (total sleep increased by 30 minutes on placebo vs 64 minutes on lemborexant 5 mg and 69 minutes on 10 mg). Zolpidem, on the other hand, outperformed placebo in terms of total sleep time and non-REM sleep, but failed to reduce REM latency.

This study is weakened by being a secondary analysis, which makes it more prone to statistical error. Also, while lemborexant did improve sleep architecture, the changes were small and their clinical relevance is unclear. On the other hand, the changes in REM sleep seen here are relevant to age-related memory decline, and separate studies have found that lemborexant protects sleep-dependent memory consolidation in older adults with insomnia (Harand C et al, Front Neurol 2012;3:8).

The benefits seen in this study are consistent with prior research on another orexin antagonist, suvorexant, suggesting the orexin antagonists may have a beneficial class effect on sleep architecture (Snyder E et al, Sleep Med 2016;19:93–100).

TCPR’s Take
Quality is as important as quantity when it comes to sleep, particularly with older adults. Though this is only one study, it’s encouraging to see a hypnotic that improves sleep architecture and may have a positive impact on memory. Lemborexant also belongs to a small group of hypnotics that are relatively safe in older adults (along with suvorexant, ramelteon, and melatonin). Unfortunately, these benefits come at a cost of $10 a pill.
General Psychiatry
KEYWORDS free_articles geriatric-psychiatry hypnotics lemborexant sleep sleep_disorders
    Garrett Rossi, MD.

    A Psychedelic Primer

    More from this author
    www.thecarlatreport.com
    Issue Date: August 3, 2021
    SUBSCRIBE NOW
    Table Of Contents
    ECT Worked: Now What?
    Turning Nightmares Into Dreams
    Lemborexant and Sleep Architecture in the Elderly
    Comparison of GI Side Effects of Antidepressants
    CME Post-Test - Therapy, TCPR, August 2021
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.